Abbott Common Stock vs Short Term Debt Analysis

ABT Stock

USD 118.77 0.18 0.15%

Abbott Laboratories financial indicator trend analysis is way more than just evaluating Abbott Laboratories prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Abbott Laboratories is a good investment. Please check the relationship between Abbott Laboratories Common Stock and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.

Common Stock vs Short Term Debt

Common Stock vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Abbott Laboratories Common Stock account and Short Term Debt. At this time, the significance of the direction appears to have weak relationship.

The correlation between Abbott Laboratories' Common Stock and Short Term Debt is 0.33. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Abbott Laboratories, assuming nothing else is changed. The correlation between historical values of Abbott Laboratories' Common Stock and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Abbott Laboratories are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Common Stock i.e., Abbott Laboratories' Common Stock and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.33

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Common Stock

Short Term Debt

Most indicators from Abbott Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Abbott Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.At this time, Abbott Laboratories' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 19.79 in 2024, whereas Tax Provision is likely to drop slightly above 949.8 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	24.5B	24.5B	22.1B	12.5B
Total Revenue	43.1B	43.7B	40.1B	22.2B

Gross Profit Total Revenue

Abbott Laboratories fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Accounts Payable	Current Deferred Revenue	Common Stock Total Equity	Short Term Investments
Total Assets		0.87	0.67	0.77	0.75	0.92	0.77	0.61	0.49	0.82	0.23	0.45	0.86	0.3	0.89	0.61	0.15	-0.05	0.97	0.41	0.74	-0.15	0.63	-0.56	0.67	-0.06
Short Long Term Debt Total	0.87		0.44	0.44	0.53	0.65	0.79	0.4	0.68	0.71	0.18	0.6	0.64	0.22	0.99	0.37	-0.03	0.0	0.95	0.18	0.68	-0.35	0.42	-0.34	0.51	-0.16
Other Current Liab	0.67	0.44		0.89	0.76	0.79	0.4	0.69	0.23	0.68	0.09	0.28	0.9	-0.17	0.46	0.75	0.5	-0.45	0.65	0.63	0.67	0.26	0.63	-0.46	0.53	0.2
Total Current Liabilities	0.77	0.44	0.89		0.68	0.86	0.37	0.62	0.27	0.58	0.13	0.32	0.91	0.02	0.46	0.62	0.57	-0.37	0.69	0.51	0.73	0.38	0.53	-0.47	0.44	0.18
Total Stockholder Equity	0.75	0.53	0.76	0.68		0.84	0.55	0.93	0.2	0.92	0.19	0.17	0.66	-0.06	0.54	0.94	0.1	0.1	0.65	0.82	0.49	-0.03	0.89	-0.83	0.94	-0.06
Property Plant And Equipment Net	0.92	0.65	0.79	0.86	0.84		0.61	0.75	0.33	0.81	0.21	0.31	0.88	0.21	0.67	0.78	0.22	-0.08	0.82	0.62	0.69	-0.03	0.74	-0.67	0.74	-0.03
Net Debt	0.77	0.79	0.4	0.37	0.55	0.61		0.29	0.09	0.82	0.35	0.03	0.6	0.42	0.85	0.4	-0.17	-0.01	0.81	0.13	0.26	-0.42	0.49	-0.32	0.61	-0.2
Retained Earnings	0.61	0.4	0.69	0.62	0.93	0.75	0.29		0.31	0.76	0.1	0.27	0.52	-0.29	0.37	0.91	0.13	0.16	0.5	0.85	0.5	0.12	0.8	-0.82	0.86	-0.09
Cash	0.49	0.68	0.23	0.27	0.2	0.33	0.09	0.31		0.17	-0.12	0.95	0.33	-0.14	0.59	0.13	0.16	0.0	0.57	0.13	0.79	-0.06	0.1	-0.17	0.11	-0.02
Non Current Assets Total	0.82	0.71	0.68	0.58	0.92	0.81	0.82	0.76	0.17		0.29	0.08	0.68	0.15	0.74	0.83	-0.09	0.05	0.79	0.64	0.39	-0.26	0.86	-0.72	0.93	-0.25
Non Currrent Assets Other	0.23	0.18	0.09	0.13	0.19	0.21	0.35	0.1	-0.12	0.29		-0.17	0.15	0.25	0.21	0.17	-0.15	0.07	0.21	0.03	-0.05	-0.08	0.24	-0.38	0.26	-0.16
Cash And Short Term Investments	0.45	0.6	0.28	0.32	0.17	0.31	0.03	0.27	0.95	0.08	-0.17		0.38	-0.23	0.52	0.07	0.37	-0.01	0.52	0.06	0.87	0.08	-0.01	-0.07	0.0	0.3
Net Receivables	0.86	0.64	0.9	0.91	0.66	0.88	0.6	0.52	0.33	0.68	0.15	0.38		0.15	0.68	0.59	0.44	-0.38	0.84	0.42	0.77	0.08	0.54	-0.36	0.46	0.21
Common Stock Shares Outstanding	0.3	0.22	-0.17	0.02	-0.06	0.21	0.42	-0.29	-0.14	0.15	0.25	-0.23	0.15		0.3	-0.04	-0.48	0.15	0.26	-0.07	-0.12	-0.62	0.21	-0.03	0.08	-0.31
Non Current Liabilities Total	0.89	0.99	0.46	0.46	0.54	0.67	0.85	0.37	0.59	0.74	0.21	0.52	0.68	0.3		0.38	-0.05	-0.01	0.96	0.17	0.64	-0.4	0.46	-0.34	0.53	-0.16
Inventory	0.61	0.37	0.75	0.62	0.94	0.78	0.4	0.91	0.13	0.83	0.17	0.07	0.59	-0.04	0.38		0.0	0.11	0.51	0.92	0.39	-0.08	0.95	-0.81	0.9	-0.15
Other Current Assets	0.15	-0.03	0.5	0.57	0.1	0.22	-0.17	0.13	0.16	-0.09	-0.15	0.37	0.44	-0.48	-0.05	0.0		-0.42	0.14	-0.03	0.56	0.81	-0.21	0.08	-0.22	0.67
Other Stockholder Equity	-0.05	0.0	-0.45	-0.37	0.1	-0.08	-0.01	0.16	0.0	0.05	0.07	-0.01	-0.38	0.15	-0.01	0.11	-0.42		-0.13	0.1	-0.18	-0.33	0.15	-0.26	0.28	-0.05
Total Liab	0.97	0.95	0.65	0.69	0.65	0.82	0.81	0.5	0.57	0.79	0.21	0.52	0.84	0.26	0.96	0.51	0.14	-0.13		0.3	0.75	-0.21	0.54	-0.43	0.58	-0.07
Property Plant And Equipment Gross	0.41	0.18	0.63	0.51	0.82	0.62	0.13	0.85	0.13	0.64	0.03	0.06	0.42	-0.07	0.17	0.92	-0.03	0.1	0.3		0.3	-0.04	0.87	-0.72	0.78	-0.18
Total Current Assets	0.74	0.68	0.67	0.73	0.49	0.69	0.26	0.5	0.79	0.39	-0.05	0.87	0.77	-0.12	0.64	0.39	0.56	-0.18	0.75	0.3		0.2	0.28	-0.29	0.25	0.34
Short Term Debt	-0.15	-0.35	0.26	0.38	-0.03	-0.03	-0.42	0.12	-0.06	-0.26	-0.08	0.08	0.08	-0.62	-0.4	-0.08	0.81	-0.33	-0.21	-0.04	0.2		-0.3	0.07	-0.28	0.43
Accounts Payable	0.63	0.42	0.63	0.53	0.89	0.74	0.49	0.8	0.1	0.86	0.24	-0.01	0.54	0.21	0.46	0.95	-0.21	0.15	0.54	0.87	0.28	-0.3		-0.83	0.92	-0.32
Current Deferred Revenue	-0.56	-0.34	-0.46	-0.47	-0.83	-0.67	-0.32	-0.82	-0.17	-0.72	-0.38	-0.07	-0.36	-0.03	-0.34	-0.81	0.08	-0.26	-0.43	-0.72	-0.29	0.07	-0.83		-0.86	0.28
Common Stock Total Equity	0.67	0.51	0.53	0.44	0.94	0.74	0.61	0.86	0.11	0.93	0.26	0.0	0.46	0.08	0.53	0.9	-0.22	0.28	0.58	0.78	0.25	-0.28	0.92	-0.86		-0.33
Short Term Investments	-0.06	-0.16	0.2	0.18	-0.06	-0.03	-0.2	-0.09	-0.02	-0.25	-0.16	0.3	0.21	-0.31	-0.16	-0.15	0.67	-0.05	-0.07	-0.18	0.34	0.43	-0.32	0.28	-0.33

Click cells to compare fundamentals

Abbott Laboratories Account Relationship Matchups

Abbott Laboratories fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	67.9B	72.5B	75.2B	74.4B	73.2B	36.9B
Short Long Term Debt Total	18.9B	19.6B	19.0B	17.7B	15.9B	9.8B
Other Current Liab	6.1B	7.1B	7.4B	8.1B	7.7B	8.1B
Total Current Liabilities	10.9B	11.9B	13.1B	15.5B	13.8B	8.3B
Total Stockholder Equity	31.1B	32.8B	35.8B	36.7B	38.6B	40.5B
Property Plant And Equipment Net	8.0B	9.0B	9.0B	9.2B	11.3B	6.2B
Net Debt	15.0B	12.8B	9.2B	7.8B	9.0B	6.1B
Retained Earnings	25.8B	27.6B	31.5B	35.3B	37.6B	39.4B
Cash	3.9B	6.8B	9.8B	9.9B	6.9B	3.7B
Non Current Assets Total	52.2B	52.1B	51.0B	49.2B	50.5B	53.1B
Non Currrent Assets Other	52.2B	3.7B	5.2B	6.0B	6.0B	3.0B
Cash And Short Term Investments	4.1B	7.1B	10.2B	10.2B	7.3B	4.3B
Net Receivables	5.4B	6.4B	6.5B	6.2B	6.6B	3.9B
Common Stock Shares Outstanding	1.8B	1.8B	1.8B	1.8B	1.8B	1.3B
Liabilities And Stockholders Equity	67.9B	72.5B	75.2B	74.4B	73.2B	36.9B
Non Current Liabilities Total	25.7B	27.6B	26.1B	22.0B	20.5B	11.7B
Inventory	4.3B	5.0B	5.2B	6.2B	6.6B	6.9B
Other Current Assets	1.8B	1.9B	2.3B	2.7B	2.3B	2.2B
Other Stockholder Equity	(10.1B)	(10.0B)	(11.8B)	(15.2B)	(16.0B)	(16.8B)
Total Liab	36.6B	39.5B	39.2B	37.5B	34.4B	20.0B
Property Plant And Equipment Gross	8.0B	9.0B	19.4B	20.2B	21.9B	23.0B
Total Current Assets	15.7B	20.4B	24.2B	25.2B	22.7B	13.3B
Accumulated Other Comprehensive Income	(8.5B)	(8.9B)	(8.4B)	(8.1B)	(7.8B)	(7.4B)
Short Term Debt	207M	1.5B	461M	999M	2.5B	2.1B
Accounts Payable	3.3B	3.9B	4.4B	4.6B	4.3B	4.5B
Common Stock Total Equity	23.9B	24.1B	24.5B	24.7B	28.4B	29.8B
Short Term Investments	280M	310M	450M	288M	383M	757.2M
Common Stock	23.9B	24.1B	24.5B	24.7B	24.9B	23.6B
Intangible Assets	17.0B	14.8B	12.7B	10.5B	8.8B	9.1B
Other Liab	8.3B	8.2B	7.8B	6.6B	7.6B	5.7B
Other Assets	2.4B	2.8B	4.1B	4.9B	5.7B	5.9B
Long Term Debt	16.7B	18.5B	17.3B	14.5B	13.6B	12.0B
Treasury Stock	(10.0B)	(10.1B)	(10.0B)	(11.8B)	(10.6B)	(10.1B)
Property Plant Equipment	8.0B	9.0B	9.0B	9.2B	10.5B	7.7B
Good Will	23.2B	23.7B	23.2B	22.8B	23.7B	15.5B
Net Tangible Assets	(70M)	3.4B	(2.2B)	11.0B	9.9B	10.4B
Noncontrolling Interest In Consolidated Entity	198M	213M	219M	222M	251.9M	163.8M
Retained Earnings Total Equity	25.8B	27.6B	31.5B	35.3B	40.5B	27.2B
Long Term Debt Total	16.7B	18.5B	17.3B	14.5B	16.7B	15.8B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Abbott Stock Analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC